Table 2 Treatment characteristics
Characteristics | n | (%) |
|---|---|---|
Radiotherapy field | ||
Whole pelvis and lower para-aortic lymphatics | 4 | 4.4 |
Whole pelvis and entire para-aortic lymphatics | 86 | 95.6 |
Chemotherapy | ||
None | 44 | 48.9 |
Concurrent chemotherapy | 46 | 51.1 |
Weekly cisplatin or carboplatin | 24 | 26.6 |
Cisplatin or carboplatin followed by 5-FU | 22 | 24.5 |
Total dose to point A (Gy) | ||
Median | 70.2 | |
Range | (56–93) | |
Interquartile range (75th and 25th percentiles) | 14.4 (80.4,66) | |
Total dose to para-aortic lymphatics | ||
Median | 50.4 | |
Range | (45–60.4) | |
Interquartile range (75th and 25th percentiles) | 3.6 (54, 50.4) | |
Radiotherapy duration (days) | ||
Median | 69 | |
Range | (43–182) | |
Interquartile range (75th and 25th percentiles) | 20 (80, 60) |